SSA
BIAF icon

Schonfeld Strategic Advisors’s bioAffinity Technologies BIAF Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.5K Buy
+24,413
New +$39.4K ﹤0.01% 1901

Other funds holding BIAF

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AAS
Ameritas Advisory Services Lincoln, Nebraska $2.58B AUM 18.84% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's BIAF Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in bioAffinity Technologies (BIAF) in Q1 2026: 24,413 shares worth $93.5K. The stake represents ﹤0.01% of the portfolio and ranks #1901 among its holdings.

14 funds tracked by Wall St. Rank hold BIAF as of Q1 2026.

  • Schonfeld Strategic Advisors held 24,413 shares of bioAffinity Technologies worth $93.5K as of Q1 2026.
  • bioAffinity Technologies was a new Schonfeld Strategic Advisors position in Q1 2026.
  • bioAffinity Technologies made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1901 holding.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.